Roorkee, Jan 20 (NationPress) A group of researchers at the Indian Institute of Technology (IIT) Roorkee revealed on Tuesday a pioneering platform for antibody discovery that could revolutionize diagnostics and treatment options for various diseases.

This research centers around creating an ultra-large, high-diversity library of single-domain antibodies, commonly known as nanobodies.

Covering a range of health issues from infectious diseases to cancer, autoimmune disorders, and emerging pathogens, this platform allows for the swift identification of antibodies that are both stable and possess high affinity.

By drastically shortening the duration of the discovery process, this breakthrough addresses a vital need in healthcare, especially during times of public health crises.

“Establishing a universal and high-diversity antibody discovery system right here in India enhances our national capabilities to respond to diseases more quickly, while also facilitating the development of affordable diagnostics and treatments for those populations that need them the most,” stated Prof. Rajesh Kumar from the Department of Biosciences and Bioengineering at IIT Roorkee.

This research aligns with the goals of Atmanirbhar Bharat and Make in India, and holds particular significance for low- and middle-income nations where timely and budget-friendly healthcare solutions are often hard to access.

The initiative emphasizes the necessity to bolster indigenous research capabilities, create intellectual property, and lessen dependency on imported biologics. It complements national strategies aimed at advancing translational research, improving pandemic preparedness, and establishing long-term resilience in healthcare.

“This advancement shows how fundamental research, when paired with a focus on practical application and collaboration with industry, can tackle significant societal challenges,” remarked Prof. K. K. Pant, Director of IIT Roorkee.

To expedite the real-world implementation of these findings, IIT Roorkee has formed a strategic partnership with industry to facilitate technology transfer, scaling, and validation of antibody-based innovations.

As part of this collaborative effort, the Institute has formalized an agreement through a Memorandum of Understanding (MoU) with IMGENEX India to foster joint research, co-develop advanced biologics, and enhance capacity in fields such as antibody engineering, diagnostics, therapeutics, and bioprocess development.